<DOC>
	<DOCNO>NCT00116012</DOCNO>
	<brief_summary>The primary focus study explore safety range dose rNAPc2 subject manage hospital typically practice early invasive strategy ( catheterization index admission ) . After completion ascend dose-ranging part trial review data Data Safety Monitoring Board ( DSMB ) , maximum tolerate dose rNAPc2 study single-arm , open-label panel ( approximately 25 subject ) rNAPc2 descend dos unfractionated heparin ( UFH ) .</brief_summary>
	<brief_title>Anticoagulation With rNAPc2 Eliminate MACE/TIMI 32</brief_title>
	<detailed_description>Acute coronary syndrome ( ACS ) , include unstable angina non-ST-elevation ( non-STE ) myocardial infarction , represent serious clinical condition affect 1,000,000 people US alone . The combined rate death myocardial infarction ( MI ) ACS patient 8-15 % one month , spite best current therapy include use low-molecular weight heparin , glycoprotein IIb/IIIa ( GPIIb/IIIa ) inhibitor , early invasive strategy . Given high prevalence disorder , improvement outcomes patient desirable . It currently believe principle cause clinical symptom characterize ACS result transient thrombotic occlusion one coronary vessel . Coronary thrombosis initiate exposure protein tissue factor ( TF ) , find sub-endothelial layer blood vessel major component atherosclerotic gruel . The exposure TF follow vascular damage rupture coronary atherosclerotic plaque , result rapid formation enzymatic complex compose TF serine protease factor VIIa ( fVIIa/TF ) . The fVIIa/TF complex initiate amplify cascade proteolytic activation step result formation serine protease thrombin . The highly amplified generation thrombin localize site vascular damage plaque rupture , couple high-shear rheological environment coronary vessel , result activation subsequent aggregation platelet formation insoluble matrix fibrin result platelet-rich thrombus . The critical role fVIIa/TF complex initiation coronary thrombosis suggest may ideal target inhibitor result attenuation thrombin generation subsequent thrombus formation . Recombinant nematode anticoagulant protein c2 ( rNAPc2 ) novel potent inhibitor fVIIa/TF may improve current therapeutic strategy reduce extent coronary thrombosis subsequent clinical event patient diagnose ACS .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Thromboplastin</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Ages 18 75 year inclusive Ischemic symptom last &gt; = 5 minute rest within prior 48 hour Able randomize within 48 hour recent ischemic event At least one follow criterion ( A , B , C ) : A. Elevation CKMB troponin upper limit normal OR B. ST segment deviation ( depression transient elevation ) least 0.5 mm OR C. TIMI risk score &gt; = 3 , define three follow : Age &gt; = 65 ; At least 3 follow risk factor : hypertension , diabetes mellitus , current smoker ( within 1 year ) , dyslipidemia , family history premature coronary artery disease ( &lt; age 60 ) ; Known prior coronary artery stenosis &gt; 50 % ; Daily aspirin use least 7 day ; &gt; = 2 ischemic episode rest last &gt; = 15 minute within prior 24 hour ; Elevation CKMB OR troponin upper limit normal ; ST segment deviation ( depression transient elevation ) least 0.5 mm . Ability understand willingness give write informed consent Planned early invasive strategy index hospitalization Index event STsegment elevation MI new LBBB CABG plan within 7 day ACS secondary nonatherosclerotic mechanism ( e.g . thyrotoxicosis , anemia ) Prior participation ANTHEMTIMI 32 , prior exposure rNAPc2 , participation study experimental drug device within 30 day Pregnancy , lactation use intrauterine device ( note : woman childbearing potential must negative bHCG ) Active renal disease , Cr &gt; 4 mg/dl , history renal transplantation History bleed diathesis recurrent bleed episode Medical comorbidities place subject risk hemorrhage , include , limited , prior cerebral hemorrhage , arteriovenous malformation , nonhemorrhagic CVA TIA , GI bleed , active PUD , advance liver renal disease . Major trauma , surgery , CNS , spinal eye surgery within 6 month , parenchymal organ biopsy within 14 day . Uncontrolled hypertension ( SBP &gt; 180 , DBP &gt; 100 ) despite 1 hour adequate treatment Gross hematuria within 1 month unless catheterize subsequently resolve Chronic warfarin ( INR &gt; 1.4 ) anticipate therapy warfarin Platelet count &lt; 120,000/mm3 randomization history thrombocytopenia ( confirm bluetop tube use sodium citrate ) Significant anemia ( M : Hg &lt; 11 g/dL , F : Hg &lt; 10 g/dL ) randomization Active liver disease ALT AST &gt; 3 x ULN felt part present ACS Fibrinolytic agent within 24 hour plan use fibrinolytics Known allergy intolerance aspirin Known allergy heparin , enoxaparin porkbased product History heparininduced thrombocytopenia ( type 1 2 ) Any condition investigator feel enrollment study would place subject unacceptable risk ( e.g . substance abuse ) Part 2 ONLY : Use LMWH Xa inhibitor ( e.g . Angiomax , Argatroban ) &gt; = 12 hour randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>acute coronary syndrome</keyword>
	<keyword>rNAPc2</keyword>
	<keyword>unstable angina</keyword>
	<keyword>Non-STE myocardial infarction</keyword>
	<keyword>ST elevation</keyword>
	<keyword>cardiac enzyme</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>factor VIIa</keyword>
	<keyword>tissue factor</keyword>
	<keyword>nematode anticoagulant protein c2</keyword>
	<keyword>anticoagulant</keyword>
	<keyword>thrombin inhibitor</keyword>
	<keyword>thrombosis</keyword>
</DOC>